Neutrophil β2-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome

George N M Gurguis, Stephanie P. Vo, Jay M. Griffith, A. John Rush

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Abnormal β2-adrenoceptor density and β2-adrenoceptor-mediated cyclic adenosine monophosphate (cAMP) responses were inconsistently reported in major depressive disorder. Tricyclic antidepressants downregulate β- adrenoceptor density and decrease coupling to G(s) protein. Abnormal β- adrenoceptor coupling may exist in major depressive disorder and may relate to treatment response. We investigated β2-adrenoceptor coupling to G(s) protein in 25 controls, 23 major depressive disorder drug-free patients and 16 major depressive disorder patients after chronic imipramine treatment using agonist displacement experiments. Pretreatment β2-adrenoceptor coupling and density were normal in patients as a whole. Chronic imipramine induced β2-adrenoceptor uncoupling. This effect was observed in treatment responders who had increased β2-adrenoceptor density in the high- conformational state and supercoupling prior to treatment. β2-adrenoceptor density decreased after imipramine treatment. Treatment non-responders had seemingly normal pretreatment β2-adrenoceptor function, which was not changed by imipramine. Differences in β2-adrenoceptor regulation in major depressive disorder may underlie treatment response. The results indirectly implicate abnormal agonist-mediated β2-adrenoceptor gene expression, protein kinase A, and protein kinase C in major depressive disorder.

Original languageEnglish (US)
Pages (from-to)135-144
Number of pages10
JournalEuropean Journal of Pharmacology
Volume386
Issue number2-3
DOIs
StatePublished - Dec 15 1999

Fingerprint

Imipramine
Adrenergic Receptors
Neutrophils
Depression
Major Depressive Disorder
Therapeutics
Proteins
Tricyclic Antidepressive Agents
Cyclic AMP-Dependent Protein Kinases
Cyclic AMP
Protein Kinase C
Down-Regulation

Keywords

  • β-adrenoceptor
  • Antidepressant
  • Anxiety
  • Coupling
  • Depression
  • G(s) protein
  • Major
  • Neutrophil
  • Tricyclic

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Neutrophil β2-adrenoceptor function in major depression : G(s) coupling, effects of imipramine and relationship to treatment outcome. / Gurguis, George N M; Vo, Stephanie P.; Griffith, Jay M.; Rush, A. John.

In: European Journal of Pharmacology, Vol. 386, No. 2-3, 15.12.1999, p. 135-144.

Research output: Contribution to journalArticle

Gurguis, George N M ; Vo, Stephanie P. ; Griffith, Jay M. ; Rush, A. John. / Neutrophil β2-adrenoceptor function in major depression : G(s) coupling, effects of imipramine and relationship to treatment outcome. In: European Journal of Pharmacology. 1999 ; Vol. 386, No. 2-3. pp. 135-144.
@article{3b5eba2023c2420f9d401663027277db,
title = "Neutrophil β2-adrenoceptor function in major depression: G(s) coupling, effects of imipramine and relationship to treatment outcome",
abstract = "Abnormal β2-adrenoceptor density and β2-adrenoceptor-mediated cyclic adenosine monophosphate (cAMP) responses were inconsistently reported in major depressive disorder. Tricyclic antidepressants downregulate β- adrenoceptor density and decrease coupling to G(s) protein. Abnormal β- adrenoceptor coupling may exist in major depressive disorder and may relate to treatment response. We investigated β2-adrenoceptor coupling to G(s) protein in 25 controls, 23 major depressive disorder drug-free patients and 16 major depressive disorder patients after chronic imipramine treatment using agonist displacement experiments. Pretreatment β2-adrenoceptor coupling and density were normal in patients as a whole. Chronic imipramine induced β2-adrenoceptor uncoupling. This effect was observed in treatment responders who had increased β2-adrenoceptor density in the high- conformational state and supercoupling prior to treatment. β2-adrenoceptor density decreased after imipramine treatment. Treatment non-responders had seemingly normal pretreatment β2-adrenoceptor function, which was not changed by imipramine. Differences in β2-adrenoceptor regulation in major depressive disorder may underlie treatment response. The results indirectly implicate abnormal agonist-mediated β2-adrenoceptor gene expression, protein kinase A, and protein kinase C in major depressive disorder.",
keywords = "β-adrenoceptor, Antidepressant, Anxiety, Coupling, Depression, G(s) protein, Major, Neutrophil, Tricyclic",
author = "Gurguis, {George N M} and Vo, {Stephanie P.} and Griffith, {Jay M.} and Rush, {A. John}",
year = "1999",
month = "12",
day = "15",
doi = "10.1016/S0014-2999(99)00749-9",
language = "English (US)",
volume = "386",
pages = "135--144",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Neutrophil β2-adrenoceptor function in major depression

T2 - G(s) coupling, effects of imipramine and relationship to treatment outcome

AU - Gurguis, George N M

AU - Vo, Stephanie P.

AU - Griffith, Jay M.

AU - Rush, A. John

PY - 1999/12/15

Y1 - 1999/12/15

N2 - Abnormal β2-adrenoceptor density and β2-adrenoceptor-mediated cyclic adenosine monophosphate (cAMP) responses were inconsistently reported in major depressive disorder. Tricyclic antidepressants downregulate β- adrenoceptor density and decrease coupling to G(s) protein. Abnormal β- adrenoceptor coupling may exist in major depressive disorder and may relate to treatment response. We investigated β2-adrenoceptor coupling to G(s) protein in 25 controls, 23 major depressive disorder drug-free patients and 16 major depressive disorder patients after chronic imipramine treatment using agonist displacement experiments. Pretreatment β2-adrenoceptor coupling and density were normal in patients as a whole. Chronic imipramine induced β2-adrenoceptor uncoupling. This effect was observed in treatment responders who had increased β2-adrenoceptor density in the high- conformational state and supercoupling prior to treatment. β2-adrenoceptor density decreased after imipramine treatment. Treatment non-responders had seemingly normal pretreatment β2-adrenoceptor function, which was not changed by imipramine. Differences in β2-adrenoceptor regulation in major depressive disorder may underlie treatment response. The results indirectly implicate abnormal agonist-mediated β2-adrenoceptor gene expression, protein kinase A, and protein kinase C in major depressive disorder.

AB - Abnormal β2-adrenoceptor density and β2-adrenoceptor-mediated cyclic adenosine monophosphate (cAMP) responses were inconsistently reported in major depressive disorder. Tricyclic antidepressants downregulate β- adrenoceptor density and decrease coupling to G(s) protein. Abnormal β- adrenoceptor coupling may exist in major depressive disorder and may relate to treatment response. We investigated β2-adrenoceptor coupling to G(s) protein in 25 controls, 23 major depressive disorder drug-free patients and 16 major depressive disorder patients after chronic imipramine treatment using agonist displacement experiments. Pretreatment β2-adrenoceptor coupling and density were normal in patients as a whole. Chronic imipramine induced β2-adrenoceptor uncoupling. This effect was observed in treatment responders who had increased β2-adrenoceptor density in the high- conformational state and supercoupling prior to treatment. β2-adrenoceptor density decreased after imipramine treatment. Treatment non-responders had seemingly normal pretreatment β2-adrenoceptor function, which was not changed by imipramine. Differences in β2-adrenoceptor regulation in major depressive disorder may underlie treatment response. The results indirectly implicate abnormal agonist-mediated β2-adrenoceptor gene expression, protein kinase A, and protein kinase C in major depressive disorder.

KW - β-adrenoceptor

KW - Antidepressant

KW - Anxiety

KW - Coupling

KW - Depression

KW - G(s) protein

KW - Major

KW - Neutrophil

KW - Tricyclic

UR - http://www.scopus.com/inward/record.url?scp=0033386760&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033386760&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(99)00749-9

DO - 10.1016/S0014-2999(99)00749-9

M3 - Article

C2 - 10618463

AN - SCOPUS:0033386760

VL - 386

SP - 135

EP - 144

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -